T2	intervention 33 53	irinotecan schedules
T3	eligibility 461 613	MBC patients who experienced disease progression after one to three chemotherapy regimens, including at least one anthracycline- or taxane-based regimen
T1	intervention-participants 789 791	52
T4	control-participants 839 841	51
T5	intervention 774 784	weekly arm
T6	control 817 834	every-3-weeks arm
T7	outcome 886 904	objective response
T8	iv-bin-percent 967 970	23%
T10	iv-cont-median 1037 1047	4.9 months
T12	iv-cont-median 1109 1119	9.7 months
T13	outcome 1180 1203	objective response rate
T14	cv-bin-percent 1208 1211	14%
T15	iv-bin-abs 972 975	one
T16	outcome 976 978	CR
T17	iv-bin-abs 980 982	11
T18	outcome 983 985	PR
T19	cv-bin-abs 1213 1217	nine
T20	outcome 1218 1220	PR
T22	cv-cont-median 1271 1281	4.2 months
T24	cv-cont-median 1343 1353	8.6 months
T25	outcome 1408 1422	well tolerated
T26	outcome 1454 1481	Grade 3 to 4 adverse events
T27	outcome 1517 1528	neutropenia
T28	iv-bin-percent 1530 1533	29%
T29	outcome 1539 1547	diarrhea
T30	iv-bin-percent 1549 1552	17%
T31	outcome 1576 1587	neutropenia
T32	cv-bin-percent 1589 1592	36%
T33	outcome 1595 1603	vomiting
T34	cv-bin-percent 1605 1608	20%
T35	outcome 1611 1618	dyspnea
T36	cv-bin-percent 1620 1623	18%
T37	outcome 1626 1632	nausea
T38	cv-bin-percent 1634 1637	16%
T39	outcome 1644 1652	diarrhea
T40	cv-bin-percent 1654 1657	12%
T41	outcome 1711 1728	good tolerability
T9	outcome 1008 1032	Median response duration
T11	outcome 1081 1104	median overall survival
T21	outcome 1242 1266	median response duration
T23	outcome 1315 1338	median overall survival
